Expert NetworkExpert InterviewLLY

Slingshot members are talking to an expert! The topic is:

Digging into the Alzheimer's Landscape with a focus on Lilly's recent TRAILBLAZER-ALZ 2 Phase 3 study compared to Biogen's Leqembi

Executed on:May 4, 2023 2:00 PM EDT
Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert
Institution: Private Practice
  • Neurologist in private practice in CA with over 25 years of clinical experience.
  • Currently manages 100 patients with Alzheimer's disease.
  • Diplomat of the American Board of Psychiatry; fellowship trained in Neuromuscular Physiology at UCSF.

Interview Goal

The call will focus on the recent data release from the TRAILBLAZER-ALZ 2 Phase 3 clinical trial on Donanemab. The call will also compare and contrast Donanemab with Remternetug and Biogen's recently approved Leqembi (lecanemab) in Alzheimer's disease.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.